Victory Capital Management
CAI

Victory Capital Management’s Caris Life Sciences CAI Stock Holding History

Victory Capital Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$252K Buy
14,161
+359
+3% +$6.43K ﹤0.01% 2212
2026
Q1 		$247K Buy
13,802
+539
+4% +$11.8K ﹤0.01% 2160
2025
Q4 		$358K Buy
+13,263
New +$374K ﹤0.01% 2088

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Victory Capital Management's CAI Position: Q2 2026 in Review

Victory Capital Management increased its Caris Life Sciences (CAI) stake by 2.6% in Q2 2026, buying an estimated $6.43K and bringing the position to 14,161 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Victory Capital Management first reported a position in CAI in Q4 2025 and has held it in 3 quarters since. The position peaked at $358K in Q4 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Victory Capital Management held 14,161 shares of Caris Life Sciences worth $252K as of Q2 2026.
  • Victory Capital Management bought 359 Caris Life Sciences shares in Q2 2026, an estimated $6.43K.
  • Caris Life Sciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2212 holding.
  • Victory Capital Management first reported a position in Caris Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • Victory Capital Management's Caris Life Sciences position peaked at $358K in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.